Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients
Status:
Completed
Trial end date:
2019-11-22
Target enrollment:
Participant gender:
Summary
Our hypothesis is that using antidepressants during the ECT has a better efficacy and longer
time to relapse/recurrence to the ECT without antidepressants. The purpose of this study is
to compare the efficacy, safety, and time to relapse/recurrence of ECT to ECT plus
agomelatine in the treatment of patients with major depressive disorder. Inpatients with
major depressive disorder for ECT will be randomly assigned to double-blind treatment with
placebo or agomelatine 50 mg/d.
Phase:
Phase 4
Details
Lead Sponsor:
Kaohsiung Kai-Suan Psychiatric Hospital
Collaborators:
Department of Health, Executive Yuan, R.O.C. (Taiwan) Ministry of Science and Technology, Taiwan